Eli Lilly plans to acquire psychedelics specialist AtaiBeckley through a multibillion-dollar deal that shows big pharma’s growing endorsement of a once-dimissed, now rapidly emerging research field.

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class ...

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.

The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum ...

J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.

The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why ...

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s ...

The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major ...